Literature DB >> 20079340

Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus.

Afia Akram1, James Schmeidler, Pavel Katsel, Patrick R Hof, Vahram Haroutunian.   

Abstract

To gain insight into ATP-binding cassette transporter A1 (ABCA1) function and its potential role in AD pathology, we analyzed the expression of the cholesterol transporter ABCA1 in postmortem hippocampus from persons at different stages of dementia and AD associated neuropathology relative to cognitively intact normal donors by quantitative polymerase chain reaction (qPCR) and Western blot. In this study clinical dementia rating (CDR) scores were used as a measure of dementia severity, whereas, Braak neuropathological staging and neuritic plaque density were used as an index of the neuropathological progression of AD. Correlation analysis showed that ABCA1 mRNA expression was significantly elevated at the earliest recognizable stage of dementia compared to persons with intact cognition. ABCA1 mRNA was also positively correlated with Braak neuropathological stages and neuritic plaque density counts. Additionally, ABCA1 mRNA levels showed robust correlation with dementia severity even after controlling for the confounding contribution of accompanying neuropathological parameters to ABCA1 mRNA expression. Western blot analyses showed that the differential expression observed at the transcriptional level is also reflected at the protein level. Thus, our study provides transcriptional and translational evidence that the expression of ABCA1, a key modulator of cholesterol transport across the plasma membrane, is dysregulated in the AD brain and that this dysregulation is associated with increasing severity of AD, whether measured functionally as dementia severity or neuropathologically as increased neuritic plaque and neurofibrillary tangle density. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20079340      PMCID: PMC2826590          DOI: 10.1016/j.brainres.2010.01.006

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  95 in total

1.  Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model.

Authors:  D M Holtzman; A M Fagan; B Mackey; T Tenkova; L Sartorius; S M Paul; K Bales; K H Ashe; M C Irizarry; B T Hyman
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

2.  Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.

Authors:  M D Ledesma; J S Da Silva; K Crassaerts; A Delacourte; B De Strooper; C G Dotti
Journal:  EMBO Rep       Date:  2000-12       Impact factor: 8.807

Review 3.  Oxysterol biosynthetic enzymes.

Authors:  D W Russell
Journal:  Biochim Biophys Acta       Date:  2000-12-15

4.  Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition.

Authors:  H M Tucker; M Kihiko-Ehmann; S Wright; R E Rydel; S Estus
Journal:  J Neurochem       Date:  2000-11       Impact factor: 5.372

5.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

Authors:  B Wolozin; W Kellman; P Ruosseau; G G Celesia; G Siegel
Journal:  Arch Neurol       Date:  2000-10

6.  Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Authors:  Robert D Bell; Abhay P Sagare; Alan E Friedman; Gurrinder S Bedi; David M Holtzman; Rashid Deane; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2006-11-01       Impact factor: 6.200

7.  Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specific genes in individual thalamic nuclei.

Authors:  William Byne; Stella Dracheva; Benjamin Chin; James M Schmeidler; Kenneth L Davis; Vahram Haroutunian
Journal:  Schizophr Res       Date:  2007-10-29       Impact factor: 4.939

8.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.

Authors:  Rashid Deane; Abhay Sagare; Katie Hamm; Margaret Parisi; Steven Lane; Mary Beth Finn; David M Holtzman; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2008-11-13       Impact factor: 14.808

9.  Association of genetic variants of ABCA1 with Alzheimer's disease risk.

Authors:  Eloy Rodríguez-Rodríguez; Ignacio Mateo; Javier Llorca; Coro Sánchez-Quintana; Jon Infante; Inés García-Gorostiaga; Pascual Sánchez-Juan; José Berciano; Onofre Combarros
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-10-05       Impact factor: 3.568

10.  Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes.

Authors:  Shingo Ito; Sumio Ohtsuki; Junichi Kamiie; Yasuko Nezu; Tetsuya Terasaki
Journal:  J Neurochem       Date:  2007-10-01       Impact factor: 5.372

View more
  21 in total

Review 1.  The effects of cholesterol on learning and memory.

Authors:  Bernard G Schreurs
Journal:  Neurosci Biobehav Rev       Date:  2010-05-12       Impact factor: 8.989

2.  Association of ApoE and LRP mRNA levels with dementia and AD neuropathology.

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Neurobiol Aging       Date:  2011-06-15       Impact factor: 4.673

3.  MiR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression.

Authors:  Jaekwang Kim; Hyejin Yoon; Cristina M Ramírez; Sang-Mi Lee; Hyang-Sook Hoe; Carlos Fernández-Hernando; Jungsu Kim
Journal:  Exp Neurol       Date:  2011-11-18       Impact factor: 5.330

Review 4.  Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2011-02       Impact factor: 3.911

5.  Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles.

Authors:  G T Lesser; M S Beeri; J Schmeidler; D P Purohit; V Haroutunian
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

6.  Endoplasmic reticulum stress mediates amyloid β neurotoxicity via mitochondrial cholesterol trafficking.

Authors:  Elisabet Barbero-Camps; Anna Fernández; Anna Baulies; Laura Martinez; Jose C Fernández-Checa; Anna Colell
Journal:  Am J Pathol       Date:  2014-05-09       Impact factor: 4.307

7.  Increased expression of RXRα in dementia: an early harbinger for the cholesterol dyshomeostasis?

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Mol Neurodegener       Date:  2010-09-15       Impact factor: 14.195

Review 8.  Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response.

Authors:  Ramón Cacabelos; Clara Torrellas
Journal:  Int J Mol Sci       Date:  2015-12-21       Impact factor: 5.923

Review 9.  Decoding the non-coding RNAs in Alzheimer's disease.

Authors:  Nicole Schonrock; Jürgen Götz
Journal:  Cell Mol Life Sci       Date:  2012-09-06       Impact factor: 9.261

Review 10.  Role of ABC transporters in the pathogenesis of Alzheimer's disease.

Authors:  Alaa H Abuznait; Amal Kaddoumi
Journal:  ACS Chem Neurosci       Date:  2012-10-11       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.